Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Eli Lilly is positioned to benefit from the booming obesity drug market, projected to grow from $15 billion in 2024 to $150 billion by 2035. With new products like the pill-form Foundayo and next-generation Retatrutide in development, analysts expect 15% annual earnings growth over the next decade. At current valuations, a $1,000 investment could potentially grow to approximately $2,580 in 10 years, suggesting the stock still offers attractive long-term returns despite its 160% surge over the past three years.